SMG1 Inhibitors

SMG1 inhibitors are primarily compounds that indirectly influence the function of SMG1 through their action on related pathways, particularly those involving kinases like mTOR and PI3K/Akt. SMG1, being a key component in the nonsense-mediated mRNA decay (NMD) pathway, is crucial for the detection and elimination of mRNA transcripts with premature termination codons. However, designing specific inhibitors for SMG1 is challenging due to the conserved nature of kinase active sites and the complexity of kinase signaling networks.

The inhibitors listed predominantly target the mTOR pathway, as there is a notable overlap and interaction between mTOR signaling and SMG1. Compounds such as Torin 1, AZD8055, PP242, Rapamycin, Ku-0063794, INK128, and WYE-354 are known mTOR inhibitors. By inhibiting mTOR, these compounds may indirectly affect SMG1, potentially influencing the NMD pathway. The mTOR pathway is involved in a wide range of cellular processes, including cell growth, proliferation, and survival. Its inhibition could thus indirectly modulate cellular contexts in which SMG1 operates, impacting the efficiency or regulation of NMD. Other compounds like GSK690693, KU-0060648, Palomid 529, and Perifosine target AKT or PI3K/Akt/mTOR pathways. These pathways are closely related to mTOR signaling and are involved in crucial cellular functions. Inhibiting these pathways can indirectly impact SMG1 activity by altering the cellular environment or signaling context that influences SMG1 function.